Cargando…

Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis

INTRODUCTION: Empagliflozin has demonstrated lower rates of cardiovascular outcomes vs. standard of care among patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). However, the impact of empagliflozin compared to other branded antihyperglycemic agents (AHAs) on total cost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raju, Aditya, Pimple, Pratik, Stafkey-Mailey, Dana, Farrelly, Eileen, Shetty, Sharash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776959/ https://www.ncbi.nlm.nih.gov/pubmed/34727356 http://dx.doi.org/10.1007/s13300-021-01173-0

Ejemplares similares

Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States
por: Reifsnider, Odette S., et al.
Publicado: (2022)

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States
por: Reifsnider, Odette, et al.
Publicado: (2020)

Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis
por: Correll, Christoph U., et al.
Publicado: (2017)

Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy
por: Raju, Aditya, et al.
Publicado: (2016)

Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events
por: Xie, Yan, et al.
Publicado: (2020)

Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement
por: Peasah, Samuel K, et al.
Publicado: (2023)

Tropical Plant Extracts as Potential Antihyperglycemic Agents
por: Manaharan, Thamilvaani, et al.
Publicado: (2012)

Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes
por: Qiu, Rong, et al.
Publicado: (2016)

Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review
por: Milonas, Dimitrios, et al.
Publicado: (2019)

Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus
por: Nargesi, Arash A., et al.
Publicado: (2021)

A risk prediction model for heart failure hospitalization in type 2 diabetes mellitus
por: Williams, Brent A., et al.
Publicado: (2019)

Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction
por: Lin, Shu Ning, et al.
Publicado: (2020)

Proximal Predictors of Long-Term Discontinuance with Noninsulin Antihyperglycemic Agents
por: Stuart, Bruce C., et al.
Publicado: (2016)

Correction to: Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
por: Dean, Bonnie B., et al.
Publicado: (2020)

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
por: Dean, Bonnie B., et al.
Publicado: (2020)

Amla as an antihyperglycemic and hepato-renal protective agent in fluoride induced toxicity
por: Vasant, Rupal A., et al.
Publicado: (2012)

Design, Synthesis and in Vivo Evaluation of Novel Glycosylated Sulfonylureas as Antihyperglycemic Agents
por: Suaifan, Ghadeer A. R. Y., et al.
Publicado: (2015)

Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
por: Ko, Seung-Hyun, et al.
Publicado: (2017)

Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
por: Ko, Seung-Hyun, et al.
Publicado: (2017)

Antihyperglycemic effect of thymoquinone and oleuropein, on streptozotocin-induced diabetes mellitus in experimental animals
por: Sangi, Sibghatullah Muhammad Ali, et al.
Publicado: (2015)

Analysis of Patents Issued in China for Antihyperglycemic Therapies for Type 2 Diabetes Mellitus
por: Zhu, Wei, et al.
Publicado: (2019)

Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials
por: Rados, Dimitris Varvaki, et al.
Publicado: (2020)

Selecting antihyperglycemic agents with proven safety: A must in COVID-19 era
por: Ghosal, Samit
Publicado: (2020)

Healthcare resource utilization in patients treated with empagliflozin in East Asia
por: Sheu, Wayne H‐H, et al.
Publicado: (2022)

Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
por: Currie, Craig J., et al.
Publicado: (2013)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
por: Hershon, Kenneth S
Publicado: (2016)

A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus
por: Hauber, A. Brett, et al.
Publicado: (2015)

Direct Costs Incurred Among Women Undergoing Surgical Procedures to Treat Uterine Fibroids
por: Harrington, Amanda, et al.
Publicado: (2020)

Antihyperglycemic Medications and Cardiovascular Risk Reduction
por: Anderson, Sarah L, et al.
Publicado: (2017)

Transitions of Care for People with Type 2 Diabetes: Utilization of Antihyperglycemic Agents Pre- and Post-Hospitalization
por: Montejano, Leslie, et al.
Publicado: (2015)

Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients
por: Cehic, Matthew G., et al.
Publicado: (2019)

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
por: Anderson, John E., et al.
Publicado: (2016)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

Fournier’s Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus
por: Khokhar, Farzam, et al.
Publicado: (2022)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States
por: Singer, David, et al.
Publicado: (2022)

Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh
por: Pathan, M D Faruque, et al.
Publicado: (2022)

Study of drug utilization pattern of antihyperglycemic agents in a South Indian tertiary care teaching hospital
por: Abdi, Sayed Aliul Hasan, et al.
Publicado: (2012)

Vanadium as potential therapeutic agent for COVID-19: A focus on its antiviral, antiinflamatory, and antihyperglycemic effects
por: Semiz, Sabina
Publicado: (2022)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_85jot0bds8t6vv9mghtfog8ko7